FDA Criticizes Bristol Myers Squibb for Misleading Efficacy Claims on Krazati Website

Bristol Myers Squibb, FDA, Krazati, misleading efficacy claims, non-small-cell lung cancer, NSCLC, KRAS G12C-mutated, cancer treatment

Tremfya Phase III Maintenance Study Results Presented by J&J for Ulcerative Colitis Treatment

J&J, Johnson & Johnson, Tremfya, guselkumab, Phase III trial, maintenance study, ulcerative colitis, inflammatory bowel disease, treatment, efficacy, safety, remission.